Eli Lilly’s Alzheimer’s treatment shows promise in early stages of disease — but safety concerns remain

Some Wall Street analysts tempered their enthusiasm about Leqembi’s approval in part because of limited capacity at hospitals and infusion centers to administer the biweekly IV infusions. Donanemab, however, is only administered every 4 weeks, which may ease the infusion issues as well as the long-term costs, geriatrics researchers from the University of California San Francisco, SUNY Upstate Medical University and the University of Wisconsin wrote in an editorial published in JAMA Monday.